Rondo Therapeutics, a privately held biopharmaceutical immuno-oncology company pioneering the development of next-generation T cell-engaging bispecific antibodies for the treatment of solid tumors, ...

It is closely associated with tumorigenesis and drug resistance, making it a potential target for oncology drug development. To date, no ROR1-targeting drugs have been marketed. BR111 utilizes ...

In the ALEXANDRA/IMpassion030 trial, Tecentriq (atezolizumab) added to postoperative chemotherapy was not found to improve ...

Mozart Therapeutics, the leading developer of CD8 Treg network modulators in autoimmune disease, announces the presentation ...

Cambridge, Massachusetts Thursday, February 6, 2025, 13:00 Hrs [IST] ...

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, /PRNewswire/ -- Harbour BioMed (HKEX: 02142, the 'Company'), a global ...

Induces potent and long-lasting immune responses to defined antigens or whole pathogens (particles), mainly through the induction of high-affinity antibodies derived from GCs and produced by ...

A breakthrough discovery in enzyme science could revolutionize the treatment of autoimmune disorders and other diseases tied to the overactivity of antibodies. Published in the journal, ...

Explore the structure of the antibody and the four main ways antibodies function when binding to pathogens with the image below. The cell-mediated response is the other path of the adaptive immune ...

Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal ...

This discovery sheds light on how tissue-resident memory CD8 T cells adapt to their location in the body, ensuring a coordinated and effective immune response and how microenvironments and cellular ...